Enhanced properties of discrete pulmonary deoxyribonuclease I (DNaseI) loaded PLGA nanoparticles during encapsulation and activity determination

International Journal of Pharmaceutics

Volumn 408, Issue 1-2, 2011, Pages 257-265

  Osman, Rihab ^a,b   Kan, Pei Lee ^a   Awad, Gehanne ^b   Mortada, Nahed ^b   El Shamy, Abd Elhameed ^b   Alpar, Oya ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b African Union Organization St Abbassia   (Egypt)

Author keywords

DNaseI; DPPC; Emulsion solvent evaporation; Leucine; Nanoparticles; Pulmonary; Radial enzyme diffusion

Indexed keywords

DEOXYRIBONUCLEASE I; POLYGLACTIN;

ARTICLE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL;

ADMINISTRATION, INHALATION; AEROSOLS; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYRIBONUCLEASE I; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; EPITHELIAL CELLS; HUMANS; LACTIC ACID; LUNG; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLUBILITY; SURFACE PROPERTIES;

EID: 79953245794     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.02.013     Document Type: Article

References (40)

1. Castellanos, I.J., Cruz, G., Crespo, R., Griebenow, K., 2002. Encapsulation-induced aggregation and loss in activity of α-chymotrypsin and their prevention. J. Control. Release 81, 307-319. (Pubitemid 34607150)
2. Cipolla, D.C., Clark, A.R., Chan, H.K., Gonda, I., Shire, S.J., 1994a. Assessment of aerosol delivery systems for the recombinant human deoxyribonuclease I (rhDNase). STP Pharm. Sci. 4, 50-62. (Pubitemid 24058060)
3. Cipolla, D.C., Gonda, I., Shire, S.J., 1994b. Characterization of aerosols of human recombinant deoxyribonuclease (rhDNase) generated by jet nebulizers. Pharm. Res. 11, 491-498.
4. De Boer, A.H., Molema, G., Frijlink, H.W., 2001. Pulmonary drug delivery: delivery to and through the lung drug targeting. In: Molema, G., Meijer, D.K.F. (Eds.), Organ-specific Strategies. Wiley-VCH, Weinheim/New York/Chichester/ Brisbane/Singapore/Toronto, pp. 53-85.
5. De Boer, A.H., Gjaltema, D., Hagedoorn, P., Frijnlink, H.W., 2002. Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. Int. J. Pharm. 249, 219-231.
6. Dellamary, L., Smith, D.J., Bloom, A., Bot, S., Guo, G.R., Deshmuk, H., Costello, M., Bot, A., 2004. Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics. J. Control. Release 95, 489-500. (Pubitemid 38340499)
7. Evora, C., Soriano, I., Rogers, R.A., Shakesheff, K.M., Hanes, J., Langer, R., 1998. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2- dipalmitoylphosphatidylcholine. J. Control. Release 51, 143-152. (Pubitemid 28252865)
8. Florindo, H.F., Pandit, S., Gonçalves, L.M.D., Alpar, H.O., Almeida, A.J., 2008. Streptococcus equi antigens adsorbed onto surface modified poly-γ-caprolactone microspheres induce humoral and cellular specific immune responses. Vaccine 26, 4168-4177.
9. Freitas, S., Merkle, H.P., Gander, B., 2005. Microencapsulation by solvent extraction/ evaporation: reviewing the state of the art of microsphere preparation process technology. J. Control. Release 102, 313-332. (Pubitemid 40093756)
10. Garcia-Contreras, L., Hickey, A.J., 2002. Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy. Adv. Drug Deliv. Rev. 54, 1491-1504.
11. Gómez, M.I., Prince, A., 2007. Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr. Opin. Pharm. 7, 244-251.
12. Gonda, I., 1996. Inhalation therapy with recombinant human deoxyribonuclease I. Adv. Drug Deliv. Rev. 19, 37-46.
13. Henke, M.O., Ratjen, F., 2007. Mucolytics in cystic fibrosis. Pediatr. Respir. Rev. 8, 24-29.
14. Hinds, W.C., 1998. Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles. Wiley, New York.
15. Jeffery, H., Davis, S.S., O'Hagan, D.T., 1993. The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of amodel protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm. Res. 10, 362-368.
16. Jones, S.A., Martin, G.P., Brown, M.B., 2006. Stabilisation of deoxyribonuclease in hydrofluoroalkanes using miscible vinyl polymers. J. Control. Release 115, 1-8. (Pubitemid 44419527)
17. Kang, F., Singh, J., 2003. Conformational stability of a model protein (bovine serum albumin) during primary emulsification process of PLGA microspheres synthesis. Int. J. Pharm. 260, 149-156.
18. Kim, T.H., Lee, H., Park, T.G., 2002. Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres. Biomaterials 23, 2311-2317. (Pubitemid 34234832)
19. Lamprecht, A., Ubrich, N., Hombreiro, P.M., Lehr, C., Hoffman, M., Maincent, P., 1999. Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification. Int. J. Pharm. 184, 97-105.
20. Nadano, D., Yasuda, T., Kishi, K., 1993. Measurement of deoxyribonuclease I activity in human tissues and body fluids by a single radial enzyme-diffusion method. Clin. Chem. 39, 445-452.
21. Pan, C.Q., Lazarus, R.A., 1999. Ca2+ dependent activity of human DNase I and its hyperactive variants. Protein Sci. 8, 1780-1788. (Pubitemid 29430478)
22. Pean, J.M., Venier-Julienne, M.C., Filmon, R., Sergent, M., Benoit, J.P., 1998. Optimization of HAS and NGF encapsulation yields in PLGA microparticles. Int. J. Pharm. 166, 105-115.
23. Pérez, C., Griebenow, K., 2001. Improved activity and stability of lysozyme at the water/methylene chloride interface: enzyme unfolding and aggregation and its prevention by polyols. J. Pharm. Pharmacol. 53, 1217-1226.
24. 2/water interface and upon water-in-oil-in-water encapsulation in PLGA microspheres. J. Control. Release 89, 71-85.
25. Phipps, P.R., Gonda, I., 1994. Evaporation of aqueous aerosols produced by jet nebulizers: effects on particle size and concentration of solution in the droplets. J. Aerosol Med. 7, 239-258.
26. Pilcer, G., Vanderbist, F., Amighia, K., 2008. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations. Int. J. Pharm. 358, 75-81.
27. Ruan, G., Feng, S.S., Li, Q.T., 2002. Effects of material hydrophobicity on physical properties of polymeric microspheres formed by double emulsion process. J. Control. Release 84, 151-160. (Pubitemid 35439142)
28. Rubin, B.K., 2007. Mucus structure and properties in cystic fibrosis. Pediatr. Respir. Rev. 8, 4-7.
29. Sabulal, B., Kishore, N., 1997. Amino acids and short peptides do not always stabilize globular proteins: a differential scanning calorimetric study on their interactions with bovine α-lactalbumin. J. Chem. Soc. Faraday Trans. 93, 433-436.
30. Sansdrap, P., Moes, A.J., 1998. Influence of additives on the release profile of nifedipine from poly(dl-lactide-co-glycolide) microspheres. J. Microencapsul. 15, 545-553. (Pubitemid 28423166)
31. Schurch, S., Gehr, P., Im Hof, V., Geiser, M., Green, F., 1990. Surfactant displaces particles toward the epithelium in airways and alveoli. Respir. Physiol. 80, 17-32.
32. Sheppard, M.N., Nicholson, A.G., 2002. The pathology of cystic fibrosis. Curr. Diagn. Pathol. 8, 50-59.
33. Sivadas, N., O'Rourke, D., Tobin, A., Buckleya, V., Ramtoola, Z., Hickey, A.J., Cryan, S.A., 2008. A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int. J. Pharm. 358, 159-167.
34. Straub, J.A., Chickering, D.E., Church, C.C., Shah, B., Hanlon, T., Bernstein, H., 2005. Porous PLGA microparticles: AI-700, an intravenously administered ultrasound contrast agent for use in echocardiography. J. Control. Release 108, 21-32. (Pubitemid 41476671)
35. Sung, J.C., Pulliam, B.L., Edwards, D.A., 2007. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 25, 563-570. (Pubitemid 350138179)
36. Tomoda, K., Makino, K., 2007. Effects of lung surfactants on rifampicin release rate from monodisperse rifampicin-loaded PLGA microspheres. Colloids Surf. B: Biointerfaces 55, 115-124. (Pubitemid 46216071)
37. Van de Weert, M., Hoechstetter, J., Hennink, W.E., Crommelin, D.J., 2000. The effect of a water/organic solvent interface on the structural stability of lysozyme. J. Control. Release 68, 351-359.
38. Wei, G., Lu, L.F., Lu, W.Y., 2007. Stabilization of recombinant human growth hormone against emulsification-induced aggregation by Pluronic surfactants during microencapsulation. Int. J. Pharm. 338, 125-132.
39. Yang, W., Peters, J.I., Williams, R.O., 2008. Inhaled nanoparticles - a current review. Int. J. Pharm. 356, 239-247.
40. Yazdanparast, R., Khodagholi, F., 2006. Kinetic aspects of alkaline phosphatase refolding in the presence of α-cyclodextrin. Arch. Biochem. Biophys. 446, 11-19.